Financial risk of the biotech industry versus the pharmaceutical industry

Applied Health Economics and Health Policy

Volumn 7, Issue 3, 2009, Pages 155-165

  Golec, Joseph ^a   Vernon, John A ^b,c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCOUNTING; BIOTECHNOLOGY; CAPITAL; DRUG INDUSTRY; DRUG RESEARCH; FINANCIAL MANAGEMENT; GOVERNMENT REGULATION; HUMAN; MARKET; PROFIT; REVIEW; RISK; UNITED STATES;

BIOMEDICAL RESEARCH; BIOTECHNOLOGY; DRUG INDUSTRY; GOVERNMENT REGULATION; HUMANS; MODELS, ECONOMIC; RISK FACTORS; UNITED STATES;

EID: 70349900241     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/bf03256149     Document Type: Review

References (17)

1. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22: 151-185
2. Grabowski HG, Vernon JM. Pioneers, imitators, and generics: a simulation model of Schumpeterian competition. Q J Eco 1987; 102 (3): 491-526
3. Vernon JA. Simulating the impact of price regulation on R&D innovation. Pharm Dev Regul 2003; 1: 55-65
4. Vernon JA. Pharmaceutical R&D: investment and cash flows. An instrumental variables approach to testing for capital market imperfections. J Pharm Finance Econ Pol 2005; 13 (4): 3-17
5. Reed SD, Califf RM, Schulman KA. How changes in drug safety regulations affect the way drug and biotech companies invest in innovation. Health Aff 2006; 25: 1309-1317
6. Standard & Poor's Compustat Resource Center [online]. Available at URL: https://www.compustatresources.com/ support/index.html [Accessed 2009 Jun 22]
7. Center for Research in Securities Prices [online]. Available at URL: http://www.crsp.com [Accessed 2009 Jun 22]
8. Vernon JA. Examining the link between price regulation and pharmaceutical R&D investment. Health Econ 2005; 14: 1-16
9. Golec J, Hegde S, Vernon J. Pharmaceutical stock price reactions to price constraint threats and firm-level R&D spending (NBER working paper # w11229) 2006 [online]. Available at URL: http://www.nber.org/papers/ [Accessed 2009 Jun 22]
10. Giaccotto C, Santerre R, Vernon J.Drug prices and research and development investment behavior in the pharmaceutical industry. J Law Econ 2005; 48: 195-214 (Pubitemid 40855318)
11. Fama EF, French KR. Common risk factors in the returns on stocks and bonds. J Fin Econ 1993; 33: 3-56
12. French KR. Data library [online]. Available at URL: http://mba.tuck. dartmouth.edu/pages/faculty/ken.french/data-library.html [Accessed 2007 Oct 12]
13. Fama EF, French KR. Industry costs of equity. J Fin Eco 1997; 43: 153-193
14. Read JL, Lee KB. Health care innovation: progress report and focus on biotechnology. Health Aff 1994; 25: 215-225 (Pubitemid 24252127)
15. Lerner J, Hilary S, Alexander T. Do equity financing cycles matter? Evidence from biotechnology alliances. J Fin Econ 2003; 67: 411-446 (Pubitemid 36224036)
16. Phillips KA. The intersection of biotechnology and pharmacogenomics: health policy implications. Health Aff 2006; 25: 1271-1280
17. Standard & Poor's 500 Stock Index [online]. Available at URL: http://www2.standardandpoors.com [Accessed 2009 Jun 22]